CFGS
VIR icon

Concourse Financial Group Securities’s Vir Biotechnology VIR Stock Holding History

Concourse Financial Group Securities’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$20 – 2365
2023
Q4 		$20 Hold
2
– – ﹤0.01% 2266
2023
Q3 		$18 Buy
+2
New +$29 ﹤0.01% 2293
2022
Q1 		– Sell
-243
Closed -$7.21K – 2452
2021
Q4 		$10K Buy
+243
New +$9.52K ﹤0.01% 1871

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Concourse Financial Group Securities's VIR Position: Q1 2024 in Review

Concourse Financial Group Securities sold out of Vir Biotechnology (VIR) in Q1 2024, closing a stake of 2 shares — an estimated $20 sold.

Concourse Financial Group Securities first reported a position in VIR in Q4 2021 and held it in 3 quarters. The position peaked at $10K in Q4 2021. 209 funds tracked by Wall St. Rank hold VIR as of Q1 2024.

  • Concourse Financial Group Securities reported no remaining Vir Biotechnology position as of Q1 2024 after selling out during the quarter.
  • Concourse Financial Group Securities sold 2 Vir Biotechnology shares in Q1 2024, an estimated $20.
  • Concourse Financial Group Securities first reported a position in Vir Biotechnology in Q4 2021 and held it in 3 quarters.
  • Concourse Financial Group Securities's Vir Biotechnology position peaked at $10K in Q4 2021.
  • 209 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2024.

Based on Concourse Financial Group Securities's 13F filing for Q1 2024, filed 1 May 2024.